Brinzolamide + Brimonidine Tartrate
Indications
This is indicated for the reduction of
elevated intraocular pressure in patients with open-angle glaucoma or
ocular hypertension.
Pharmacology
Brinzolamide is a carbonic anhydrase
inhibitor which reduce intraocular pressure (IOP) by decreasing aqueous
humor secretion in the ciliary processes of the eye.
Brimonidine Tartrate is an alpha 2 adrenergic receptor agonist which reduces IOP by decreasing aqueous humor production and increasing uveoscleral outflow.
Brimonidine Tartrate is an alpha 2 adrenergic receptor agonist which reduces IOP by decreasing aqueous humor production and increasing uveoscleral outflow.
Dosage & Administration
Instill one drop in the affected eye(s)
three times daily. If more than one topical ophthalmic drug is being
used, the drugs should be administered at least five minutes apart.
Shake well before use.
Interaction
In patients treated with this drop rare
instances to drug interactions have occurred with high-dose salicylate
therapy, CNS Depressants, Antihypertensives/ Cardiac Glycosides,
Tricyclic Antidepressants, Monoamine Oxidase Inhibitors. Therefore, the
potential for such drug interactions should be considered in patients
receiving Brinzolamide + Brimonidine Tartrate .
Contraindications
It is contraindicated in patients who are
hypersensitivity to Brinzolamide, Brimonidine Tartrate, or to any
ingredient in the formulation and Neonates and Infants (under the age of
2 years).
Side Effects
The most commonly reported side effects include blurred vision, eye irritation, bad taste and dry mouth.
Pregnancy & Lactation
Pregnancy category C. There are no adequate
and well-controlled studies in pregnant women. Brinzolamide and
Brimonidine Tartrate ophthalmic suspension should be used during
pregnancy only if the potential benefit justifies the potential risk to
the fetus.
It is not known whether Brinzolamide or Brimonidine Tartrate are excreted in human milk. Caution should be exercised while giving this ophthalmic suspension to a nursing mother.
It is not known whether Brinzolamide or Brimonidine Tartrate are excreted in human milk. Caution should be exercised while giving this ophthalmic suspension to a nursing mother.
Precautions & Warnings
Shake well before use. For ophthalmic use
only. Contact lenses should be removed during instillation of
Brinzolamide and Brimonidine Tartrate ophthalmic suspension, but may be
reinserted 15 minutes after instillation.
Use in Special Populations
Use in children: Safety & effectiveness in children below the age of 2 years have not been established.
Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
Overdose Effects
Although no human data are available,
electrolyte imbalance, development of an acidotic state, and possible
nervous system effects may occur following an oral overdose of
Brinzolamide. Serum electrolyte levels (particularly potassium) and
blood pH levels should be monitored. Very limited information exists on
accidental ingestion of Brimonidine Tartrate in adults; the only adverse
event reported to date has been hypotension. Symptoms of Brimonidine
Tartrate overdose have been reported in neonates, infants, and children
receiving Brimonidine Tartrate as part of medical treatment of
congenital glaucoma or by accidental oral ingestion. Treatment of an
oral overdose includes supportive and symptomatic therapy; a patent
airway should be maintained.
Therapeutic Class
Drugs for miotics and glaucoma
Storage Conditions
Store at room temperature & protect
from light. Do not touch dropper tip to any surface. It is desirable
that the contents should not be used more than one month after first
opening of the bottle. Shake well before use & do not freeze.
Showing 1 to 6 of 6 (1 Pages)